Harvard Bioscience Inc. (NASDAQ: HBIO) is involved in stem cell research and production. The company also supplies products for the life sciences industry. The stock is up 20 percent this year as investors catch on to the potential of this company as it reorganizes itself into two separate divisions. By spinning off part of the business, HBIO is set to grow earnings by 20 percent a year, meaning there is still plenty of room for the stock to climb from its present position.................